Macular Disease
Conditions
Brief summary
Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Interventions
Sponsors
Kyoto University, Graduate School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who visit Department of Ophthalmology Kyoto University Hospital with macular diseases. * Patients who are agreed with the participation of this study.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Initial factors associated with visual prognosis in each macular disease | Five years after the registration |
Secondary
| Measure | Time frame |
|---|---|
| The difference in the visual prognosis depending on the treatments in each macular diseases | Five years after the registration |
Other
| Measure | Time frame |
|---|---|
| The change in visual acuity in each macular diseases. | Five years after the registration. |
Countries
Japan
Contacts
Primary ContactAkitaka Tsujikawa, MD
Outcome results
None listed